Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Status:	Recruiting
Conditions:	Blood Cancer, Hematology, Hematology
Therapuetic Areas:	Hematology, Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	12/14/2018
Start Date:	October 16, 2017
End Date:	April 2020
Contact:	Vilia Dragovoy
Email:	clinicaltrialsdisclosuredesk@glenmarkpharma.com
Phone:	(201) 684-8000

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose- Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects With Previously Treated Multiple Myeloma

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD)
of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.

Inclusion Criteria:

- Males or females with multiple myeloma who have exhausted available standard
therapies.

- Measurable disease, defined as any quantifiable monoclonal protein value

- ECOG performance-status score of 2 or less

- Life expectancy of at least 3 months

- Recovered from any previous surgery and no history of major surgery within the last 28
days prior to start of study drug

Exclusion Criteria:

- Any condition that, in the opinion of the Investigator, would interfere with
evaluation of the study drug or interpretation of subject safety or study results.

- Active infectious disease considered by the Investigator to be incompatible with the
protocol.

- Evidence of clinically significant cardiovascular and respiratory conditions

- Anti-myeloma treatment within 2 weeks

- Use of any investigational drug within the past 4 weeks

We found this trial at

sites

Glenmark Investigational Site 3

Baltimore, Maryland 21287

from

Baltimore, MD